<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310518</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 501-221</org_study_id>
    <nct_id>NCT00310518</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma</brief_title>
  <official_title>A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the overall response rate (ORR) of persistent,
      recurrent or metastatic leiomyosarcoma in patients treated with ARQ 501.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 501</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide signed and dated informed consent prior to study-specific screening
             procedures.

          -  Histologically or cytologically confirmed leiomyosarcoma that is persistent, recurrent
             or metastatic.

          -  Measurable disease as defined by RECIST.

          -  Karnofsky performance status &gt;= 70%

          -  Male or female patients of child-producing potential must agree to use contraception
             or avoidance of pregnancy measures during the study and for 30 days after the last
             infusion of ARQ 501.

          -  Hemoglobin (Hgb) &gt;= 10 g/dL.

          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L (&gt;= 1,500/mm3).

          -  Platelet count &gt;= 100 x 10^9/L (&gt;= 100,000/mm3).

          -  Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) or less than
             or equal to 3.0 x ULN with metastatic liver disease.

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal
             to 2.5 x ULN less than or equal to 5.0 ULN with metastatic liver disease.

          -  Creatinine less than or equal to 1.5 x ULN.

        Exclusion Criteria:

          -  Received three or more prior anticancer chemotherapy regimens.

          -  Have active, uncontrolled systemic infection considered opportunistic, life
             threatening or clinically significant at the time of treatment.

          -  Have received anticancer chemotherapy, immunotherapy, radiotherapy, surgery or
             investigational agents within four weeks of first infusion.

          -  Have symptomatic or untreated central nervous system (CNS) involvement.

          -  Are pregnant or breastfeeding.

          -  Previous exposure to ARQ 501.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Premiere Oncology of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology Hematology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2006</study_first_posted>
  <last_update_submitted>April 28, 2009</last_update_submitted>
  <last_update_submitted_qc>April 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beta-lapachone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

